Corcept Therapeutics Inc. CEO Joe Belanoff won a 10.1 percent raise for 2013 after his Menlo Park company last year landed approval of its first drug. Belanoff's new base salary is $530,000, compared with his 2012 salary of $481,097, the company reported in a Securities and Exchange Commission filing Tuesday. Corcept (NASDAQ: CORT) also said Chief Financial Officer G. Charles Robb and vice president of commercial operations Steven Lo will receive 10 percent raises for 2013. Robb's base salary will be $340,000, and Lo will make $350,000.
